Servier promised that interim data from a phase 3 study would “shift the treatment paradigm” for a type of brain cancer that has long been stagnant in clinical research in March. Now, we’ve got the goods.

The rising antibody-drug conjugate class has hit a setback as Seagen’s Adcetris, one of the earliest and fast-growing members of the group, was defeated by immune checkpoint inhibitor in classical Hodgkin lymphoma.

While many of the companies currently developing blood tests to help diagnose cancer or track the disease’s progression are churning out physical tests that can be sent out to labs and hospitals around the world, C2i Genomics is taking a different approach.

AstraZeneca and Daiichi Sankyo’s Enhertu has already made waves in breast cancer treatment. Now, the companies are positioning the HER2 antibody-drug conjugate for expansion into other tumor types with data that researchers view as very compelling.

Regeneron believes its LAG-3 inhibitor and PD-1 inhibitor combo for patients with advanced melanoma could serve as a rival to Bristol Myer Squibb’s Opdualag, although a significant portion of patients discontinued treatment in a phase 1 study.

Bristol Myers Squibb's Breyanzi is the first CAR-T drug to deliver a positive readout in chronic lymphocytic leukemia in a pivotal multicenter study. But the study's small size and its single-arm nature might raise uncertainties for drug regulators.

Affimed is rethinking development of its bispecific innate cell engager after getting a look at phase 1/2a monotherapy data. The biotech saw two partial responses in 15 patients, resulting in data that fell short of the continuation criteria but offered enough encouragement for it to plot more combination work.

Bristol Myers Squibb’s Reblozyl could be an effective initial treatment for anemia patients who are suffering from myelodysplastic syndromes and are at a relatively lower risk of progression, an ASCO expert argues. But weak data in a key patient subgroup could raise questions.

After a massive tumor progression showing, AstraZeneca hopes new life extension data could expel whatever doubt that remains for using Tagrisso early in non-small cell lung cancer.

A year after its neuromodulation device became the first non-drug treatment cleared by the FDA to relieve chronic pain associated with fibromyalgia, NeuroMetrix is one step closer to adding another first-of-its-kind indication to the technology.

Keytruda’s first-in-class FDA approval as a first-line therapy in metastatic cervical cancer arrived in 2021 with a restriction. Now, researchers say new patient survival data suggest the Merck drug could be used in a broader patient population.

Detailed data at ASCO 2023 showed how Merck's Keytruda and Roche's Tecentriq failed to improve outcomes for patients who had tried prior standard treatment in EGFR-mutated non-small cell lung cancer and kidney cancer, respectively.